Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2
Eligibility Criteria
Inclusion Criteria: Patient has type 2 diabetes mellitus (T2DM) Patient is 18 years of age (or older) Patient is not pregnant or breast-feeding and does not plan to become pregnant for the duration of the study and poststudy follow-up period Exclusion Criteria: Patient has a history of type 1 diabetes mellitus or a history of ketoacidosis Patient required insulin within the prior 8 weeks Patient is on a weight loss program and is not in the maintenance phase Patient started on a weight loss medication (e.g., orlistat or sibutramine) within the prior 8 weeks Patient is on or likely to require treatment with treatment with immunosuppressive agents (e.g., cyclosporin, methotrexate) Patient has cirrhosis, active liver disease (other than fatty liver) or symptomatic gallbladder disease Patient has chronic myopathy, or a progressive neurological or neuromuscular disorder (e.g., multiple sclerosis or polymyositis) Patient has any of the following disorders within the past 6 months: Acute coronary syndrome (e.g., MI or unstable angina), Coronary artery intervention, Stroke or transient ischemic neurological disorder. Patient has new or worsening signs or symptoms of coronary heart disease within the past 3 months Patient has severe peripheral vascular disease Patient has congestive heart failure Patient is HIV positive Patient has a clinically important hematological disorder (e.g., aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia) Patient has a history of neoplastic disease Patient has a history of alcohol or drug abuse within the past 3 years Patient has viral hepatitis (hepatitis B or C)
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Sitagliptin 100 mg
Placebo
Sitagliptin 100 mg
Placebo